MyFinsight
Home
Blog
About
Net proceeds from
stock issuances
$323,832K
Proceeds from issuance of
stock from employee...
$825K
(211.32%↑ Y/Y)
Net cash provided by
financing activities
$324,657K
(122412.08%↑ Y/Y)
Net increase
(decrease) in cash and cash...
$11,725K
(320.73%↑ Y/Y)
Canceled cashflow
$312,932K
Sales and maturities
of marketable...
$150,510K
(-59.09%↓ Y/Y)
Accounts payable and
accrued expenses
$10,137K
(252.85%↑ Y/Y)
Stock-based compensation
expense
$8,408K
(-54.57%↓ Y/Y)
Depreciation and
amortization
$902K
(-48.16%↓ Y/Y)
Loss on sale or
disposal of assets
-$1K
(83.33%↑ Y/Y)
Net cash (used in)
provided by investing...
-$255,522K
(-375.35%↓ Y/Y)
Net cash used in
operating activities
-$57,410K
(41.64%↑ Y/Y)
Canceled cashflow
$150,510K
Canceled cashflow
$19,448K
Purchases of marketable
securities
$402,853K
(46.98%↑ Y/Y)
Net loss
-$73,503K
(33.42%↑ Y/Y)
Acquisition of property and
equipment
$3,179K
(220.14%↑ Y/Y)
Amortization and premium of
marketable securities, net
$1,698K
(-57.07%↓ Y/Y)
Prepaid and other
current assets
$1,167K
(138.64%↑ Y/Y)
Other liabilities
-$490K
(71.58%↑ Y/Y)
Back
Back
Cash Flow
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)
source: myfinsight.com